独立董事 2024 年度述职报告 福建青松股份有限公司 二、2024 年度履职概况 （一）出席董事会、股东大会会议情况 报告期内，本人积极参加公司召开的股东大会和董事会，认真履行独立董事 的各项职责。 1 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为福建青松股份有限公司（以下简称"公司"或"青松股份"）的独 立董事，在 2024 年度严格按照《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司独立董事管理办法》 《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称《规 范运作指引》）等相关法律法规、规章、规范性文件以及《公司章程》和《独立 董事工作制度》的相关规定和要求，诚实、勤勉、独立地履行职责，以独立、公 正的精神对公司重大经营事项、法人治理等方面的问题积极献计献策。现就本人 2024 年度履行职责情况报告如下： 一、个人基本情况 黄浩：1979 年出生，中国国籍，无永久境外居留权，南昌大学法学学士， 中山大学法律硕士。曾任广东通法正承 ...

董事会对独立董事独立性评估的专项意见 福建青松股份有限公司 董事会 二〇二五年四月二十六日 董事会对独立董事独立性评估的专项意见 福建青松股份有限公司（以下简称"公司"）董事会根据《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等要求，并结合公司在任独立董事唐清泉先生、钱晓明先生、黄浩 先生提交的《独立董事独立性自查情况表》，对公司独立董事独立性情况进行评 估并出具如下专项意见： 经核查，独立董事唐清泉先生、钱晓明先生、黄浩先生的任职经历以及签署 的相关自查文件，公司董事会认为上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东单位担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事 独立性的情况。公司独立董事符合《上市公司独立董事管理办法》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事 独立性的相关要求。 福建青松股份有限公司 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.94 billion, a decrease of 1.51% compared to ¥1.97 billion in 2023[22]. - The net profit attributable to shareholders for 2024 was approximately ¥54.68 million, a significant increase of 180.02% from a loss of ¥68.34 million in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥55.40 million, up 201.95% from a loss of ¥54.34 million in 2023[22]. - The net cash flow from operating activities for 2024 was approximately ¥179.16 million, an increase of 14.40% compared to ¥156.60 million in 2023[22]. - The basic earnings per share for 2024 was ¥0.1085, a turnaround from a loss of ¥0.1323 per share in 2023, representing an increase of 182.01%[22]. - The total assets at the end of 2024 were approximately ¥2.13 billion, a decrease of 10.26% from ¥2.37 billion at the end of 2023[22]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥1.30 billion, a slight decrease of 0.91% from ¥1.31 billion at the end of 2023[22]. - The weighted average return on net assets for 2024 was 4.24%, an improvement of 9.32 percentage points from -5.08% in 2023[22]. Revenue Breakdown - The facial mask series generated revenue of ¥814,793,644.65, accounting for 42.01% of total revenue, with a year-on-year increase of 1.84%[105]. - The skincare series revenue reached ¥738,615,814.93, representing 38.08% of total revenue, with a year-on-year increase of 5.11%[105]. - The wet wipes series saw a revenue decline of 5.37%, generating ¥291,031,323.17, which is 15.00% of total revenue[105]. - The total sales amount from the top five customers reached ¥649,191,787.74, accounting for 33.47% of the annual sales[115]. - The sales amount from the top five customers increased by 6.49% year-on-year, with their proportion rising by 2.51% compared to the previous year[115]. - The total procurement amount from the top five suppliers was ¥173,454,190.87, representing 16.72% of the annual procurement[117]. Market Trends - The retail sales of cosmetics in China for 2023 reached 414.2 billion CNY, with an expected increase to 435.7 billion CNY in 2024, indicating a stable growth trend in the market[57]. - The global beauty and personal care market is projected to grow to $651.6 billion in 2024, with an annual growth rate of 3.37% from 2025 to 2029[54]. - The cosmetics industry in China has seen the closure of 1,318 companies, indicating a trend towards the elimination of outdated production capacity and optimization of the industry structure[59]. - The domestic cosmetics market is shifting towards product innovation and enhanced user experience to address growth pressures and achieve sustainable development[57]. - The online cosmetics transaction scale in China is expected to grow by 5.86% to CNY 691.05 billion in 2024, accounting for 64.35% of the market, while offline sales are projected to decline by 2.28% to CNY 382.77 billion, representing 35.65%[65]. Research and Development - The company holds a total of 124 patents, including 61 invention patents, 53 utility model patents, and 10 design patents, indicating a strong focus on R&D and innovation[76]. - The company has a professional R&D team of over 180 members, continuously working on new product development to meet diverse customer needs[76]. - The company is actively engaging in industry-academia-research collaborations to enhance its technological innovation capabilities[79]. - The R&D department will concentrate on technological skincare, enhancing collaboration with universities and research institutions for raw material innovation[154]. - The company has successfully screened various herbal components for hair and skin care, aiming to enhance product market share and coverage[121]. Operational Efficiency - The company has established a strong competitive advantage through its talent, customer resources, supply chain resources, R&D innovation capabilities, and strict quality control systems[79]. - The company has reduced rental expenses by gradually subleasing redundant factories and warehouses, contributing to improved operational efficiency[92]. - The company is focused on improving organizational efficiency and decision-making processes to respond quickly to market demands[156]. - The company has established a project platform to accelerate R&D conversion and optimize order management capabilities[151]. - The company aims to introduce more digital and automated equipment to improve lean production levels and competitiveness[152]. Risk Management - The company has outlined potential risks and countermeasures in its future development outlook section[5]. - The cosmetics industry is facing operational risks due to changes in the macroeconomic environment and industry dynamics, prompting the company to closely monitor industry changes and adjust strategies accordingly[159]. - The company aims to enhance its risk prevention and control capabilities by improving internal control systems and increasing audit efforts to minimize various risks[157]. Corporate Governance - The company has no controlling shareholder or actual controller, ensuring independent operations in business, personnel, assets, and finance[178]. - The board of directors consists of 6 members, including 3 independent directors, and held 8 meetings during the reporting period[179]. - The supervisory board has 3 members, including 1 employee representative, and convened 5 meetings during the reporting period[180]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors[182][183]. - The company maintains independence in business operations, with no competition or unfair transactions with the largest shareholder[187]. Future Outlook - The company plans to focus on customer needs and increase R&D investment to enhance sustainable profitability and market share[147]. - In 2025, the company aims to implement a dual focus strategy on "customer" and "product" to optimize production management and enhance core competitiveness in the cosmetics business[148]. - The company will accelerate digital transformation to improve operational efficiency and establish itself as a leader in the local ODM cosmetics industry[150]. - The company is focusing on product innovation and market expansion, participating in major industry exhibitions and forums to showcase its R&D achievements[100].

Revenue and Profitability - The company's revenue for Q1 2025 was CNY 418,793,456.94, representing a 10.17% increase compared to CNY 380,141,658.07 in the same period last year[3] - Net profit attributable to shareholders was CNY 1,909,572.83, a significant turnaround from a loss of CNY 5,999,668.12, marking a 131.83% improvement[3] - Basic and diluted earnings per share improved to CNY 0.0038, compared to a loss of CNY 0.0116 in the same quarter last year, reflecting a 132.76% increase[3] - The net profit for Q1 2025 was ¥891,589.90, a significant recovery from a net loss of ¥6,509,642.34 in the previous year[24] - The company reported a gross profit margin of approximately 0.1% for Q1 2025, compared to a negative margin in the same period last year[24] Cash Flow and Financial Management - The net cash flow from operating activities increased by 382.22% to CNY 148,593,372.63, up from CNY 30,814,578.58 in the previous year[3] - The company's cash flow management showed improvement, with a reduction in financial expenses from ¥2,861,713.71 to -¥545,327.22[23] - Cash inflow from sales of goods and services reached ¥613,849,851.40, up from ¥499,279,761.85, representing a year-over-year increase of about 23%[26] - The total cash outflow from operating activities decreased slightly to ¥469,837,466.94 from ¥481,718,287.09, indicating improved cash management[26] - The net cash flow from investing activities was negative at -¥7,797,841.67, an improvement from -¥61,265,768.97 in the previous period, showing a reduction in cash outflow[26] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2,203,983,438.87, up 3.58% from CNY 2,127,749,012.89 at the end of the previous year[4] - Total current assets increased to ¥1,374,279,732.44 from ¥1,295,431,230.84, reflecting a growth of approximately 6.1%[20] - Total liabilities rose to ¥885,770,336.61, compared to ¥816,487,771.74, marking an increase of 8.5%[22] - The company's equity increased to ¥1,318,213,102.26, up from ¥1,311,261,241.15, indicating a growth of 0.5%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,162[16] - The largest shareholder, North Bell (Hong Kong) Nonwoven Products Co., Ltd., holds 9.17% of shares, totaling 47,392,045 shares[16] - The top ten shareholders include several entities with significant stakes, indicating a diverse ownership structure[16] Investment and Expenses - Investment income showed a decline of 513.41%, resulting in a loss of CNY 576,484.49, mainly due to discount fees on bank acceptance bills[12] - Research and development expenses were ¥12,900,015.08, slightly higher than ¥12,456,270.19 in the previous year, reflecting a focus on innovation[23] - The company plans to continue focusing on cash flow management and reducing financial expenses, as indicated by a 119.06% decrease in financial costs[12] Cash and Cash Equivalents - The company reported a significant increase in cash and cash equivalents, which rose by 53.19% to CNY 133,698,477.23[14] - The company's cash and cash equivalents increased to ¥666,495,152.52 from ¥443,159,884.69, representing a growth of approximately 50.5%[20] - The ending balance of cash and cash equivalents was ¥555,973,061.98, down from ¥757,829,167.48, indicating a decrease in liquidity[27]

Financial Performance - The company expects a net profit attributable to shareholders of 47 million to 61 million yuan for 2024, a significant increase of 168.77% to 189.26% compared to a loss of 68.34 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be between 47.5 million and 61.5 million yuan, reflecting a growth of 187.41% to 213.18% from a loss of 54.34 million yuan in the previous year [2]. - Non-recurring gains and losses are expected to impact net profit by approximately -500,000 yuan [5]. - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report [6]. Operational Improvements - The increase in performance is attributed to ongoing innovation in cosmetic raw materials and product formula optimization, leading to improved product competitiveness and a rise in gross profit margin [5]. - The company has focused on cost reduction and efficiency improvement across the supply chain, resulting in a further decrease in raw material procurement costs during the reporting period [5]. - Digital factory construction has been a key initiative to enhance digital and scientific management, optimizing customer service processes and production procedures, thereby reducing material waste and improving operational efficiency [5]. - The company has prudently arranged capital expenditures, gradually vacating redundant factories and warehouses, which has led to a decrease in asset depreciation and amortization during the reporting period [5].

2024 年第二次临时股东大会决议公告 证券代码：300132 证券简称：青松股份 公告编号：2024-059 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 12 月 26 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为 2024 年 12 月 26 日 9:15—15:00 期间的任意时间。 2、现场会议召开地点：广东省中山市南头镇东福北路 50 号青松股份中山分 公司会议室 福建青松股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： ·本次股东大会无否决或修改议案的情况； ·本次股东大会无涉及变更前次股东大会决议。 一、会议召开情况 1、会议召开时间：2024 年 12 月 26 日（星期四）下午 15:30 （1）现场会议召开时间：2024 年 12 月 26 日（星期四）下午 15:30 （2）网络投票时间：2024 年 12 月 26 日 3、会议召开方式：本次股东大会采用现场表决与网络 ...

北京市君合（广州）律师事务所 关于 福建青松股份有限公司 2024 年第二次临时股东大会的 法律意见书 二零二四年十二月 | 北京总部 | 电话: (86-10) 8519-1300 | 上海分所 | 电话: (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: (86-10) 8519-1350 | | 传真: (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: (86-571)2689-8188 | 成都分所 | 电话: (86-28) 6739-8000 | 青岛分所 | 电话: (86-532)6869-5000 | 大连分所 | 电话: (86-411) 8250-7578 | | | 传真: (86-571)2689-8199 | | 传真: (86-28 ...

关于拟变更 2024 年度审计机构的公告 证券代码：300132 证券简称：青松股份 公告编号：2024-057 福建青松股份有限公司 关于拟变更 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2023 年度审计意见为标准无保留意见； 2、公司拟聘任的审计机构为天健会计师事务所（特殊普通合伙）（以下简称 "天健事务所"），原聘任的审计机构为大华会计师事务所（特殊普通合伙）（以 下简称"大华事务所"）； 3、大华事务所在担任公司审计机构期间坚持独立审计原则，切实履行了审 计机构应尽职责。综合考虑公司业务发展、审计工作需求等情况，公司决定不再 聘任原审计机构大华事务所。公司已就本次变更年度审计机构有关事项与前任审 计机构进行了充分沟通，前任审计机构已知悉本事项并对本次变更无异议； 一、 拟聘任年度审计机构的基本情况 （一）机构信息 1、基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | | --- | --- | --- | --- | --- | --- | --- ...

第五届董事会第十二次会议决议公告 证券代码：300132 证券简称：青松股份 公告编号：2024-055 福建青松股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 福建青松股份有限公司（以下简称"公司"或"青松股份"）第五届董事会 第十二次会议于 2024 年 12 月 4 日以直接送达或电子邮件方式发出会议通知，本 次会议于 2024 年 12 月 10 日下午在青松股份中山分公司会议室以现场结合通讯 的方式召开。会议应出席董事 6 名，实际出席董事 6 名，会议由董事长范展华先 生主持，董事会秘书、监事及其他高级管理人员列席了本次会议。会议召开符合 《中华人民共和国公司法》（以下简称《公司法》）等法律法规以及《福建青松股 份有限公司章程》（以下简称《公司章程》）的规定，会议召开合法、有效。 二、董事会会议审议情况 经与会董事认真审议，并以记名投票表决方式通过如下决议： 1、审议通过《关于聘任 2024 年度审计机构的议案》； 经综合考虑公司业务发展、审计工作需求等情况，公司拟聘任天健会计 ...

关于召开 2024 年第二次临时股东大会的通知 证券代码：300132 证券简称：青松股份 公告编号：2024-058 福建青松股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 福建青松股份有限公司（以下简称"公司""本公司"或"青松股份"）根 据 2024 年 12 月 10 日召开的第五届董事会第十二次会议决议，定于 2024 年 12 月 26 日（星期四）下午 15:30 召开 2024 年第二次临时股东大会，现将召开本次 会议有关事宜通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年第二次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：经公司第五届董事会第十二次会议审议通过， 决定召开 2024 年第二次临时股东大会，召集程序符合有关法律、行政法规、部 门规章、规范性文件和《福建青松股份有限公司章程》（以下简称《公司章程》） 的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 12 月 26 日（星期四）下午 15:30 （ ...